Your browser is no longer supported. Please, upgrade your browser.
Settings
GNPX Genprex, Inc. daily Stock Chart
GNPX [NASD]
Genprex, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own2.70% Shs Outstand27.00M Perf Week94.53%
Market Cap143.91M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.37M Perf Month182.01%
Income-11.70M PEG- EPS next Q- Inst Own3.50% Short Float13.74% Perf Quarter759.68%
Sales- P/S- EPS this Y-253.40% Inst Trans-72.10% Short Ratio0.26 Perf Half Y459.64%
Book/sh0.22 P/B24.23 EPS next Y- ROA-172.30% Target Price5.00 Perf Year258.92%
Cash/sh0.09 P/C57.56 EPS next 5Y- ROE-186.70% 52W Range0.23 - 5.75 Perf YTD1565.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.30% Beta-
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low2207.36% ATR0.66
Employees7 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)77.67 Volatility31.40% 23.16%
OptionableNo Debt/Eq0.03 EPS Q/Q-0.70% Profit Margin- Rel Volume1.79 Prev Close4.38
ShortableYes LT Debt/Eq0.00 EarningsNov 19 Payout- Avg Volume6.57M Price5.33
Recom2.00 SMA20152.49% SMA50396.03% SMA200444.59% Volume11,733,312 Change21.69%
Apr-29-19Initiated Noble Capital Markets Outperform $5
Feb-21-20 04:15PM  Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants Business Wire +21.69%
Feb-20-20 10:22AM  Those Golden Rule TheStreet.com +12.31%
Feb-19-20 09:23AM  Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants Business Wire -20.41%
08:05AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPX Benzinga
Feb-11-20 08:17AM  Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes Business Wire +29.84%
Feb-06-20 08:17AM  Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire -6.99%
Feb-05-20 09:00AM  Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) Business Wire
Feb-03-20 08:17AM  Genprex to Present at NobleCon16 Investor Conference Business Wire -7.18%
Jan-29-20 08:18AM  Independent Researchers Find Genprexs TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy Business Wire +23.44%
Jan-28-20 08:00AM  Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering Business Wire
Jan-24-20 07:00AM  Genprex: The Bad and the Good of Capital Raises TheStreet.com -8.57%
Jan-23-20 09:00AM  Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market Business Wire -25.93%
Jan-22-20 10:54AM  Genprex's stock rallies on FDA fast-track designation MarketWatch +64.35%
Jan-21-20 08:00AM  Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer Business Wire +219.44%
Jan-06-20 08:00AM  Genprex to Present at Biotech Showcase 2020 in San Francisco Business Wire +7.44%
Nov-20-19 11:15AM  Genprex Announces $1.26 Million Registered Direct Offering Business Wire -43.55%
Nov-19-19 08:00AM  Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers Business Wire +60.29%
Nov-04-19 08:00AM  Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month Business Wire
Oct-15-19 08:00AM  MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-09-19 08:00AM  Genprex to Present at the MicroCap Rodeo Investor Conference Business Wire -6.86%
Oct-07-19 08:00AM  Genprexs Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support Business Wire -8.00%
Sep-26-19 08:30AM  Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment GlobeNewswire
Sep-25-19 08:30AM  Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments GlobeNewswire
Sep-18-19 08:00AM  Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019 Business Wire
Sep-11-19 08:00AM  Independent Researchers Find Genprexs TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer Business Wire
Sep-07-19 04:35PM  CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Sep-06-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments GlobeNewswire
Sep-04-19 01:43PM  Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck Business Wire
Aug-23-19 08:30AM  Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector GlobeNewswire
Aug-22-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Companys Milestone Achievements GlobeNewswire
Aug-21-19 03:31PM  What Kind Of Investor Owns Most Of Genprex, Inc. (NASDAQ:GNPX)? Simply Wall St.
08:00AM  Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference Business Wire
Aug-13-19 08:00AM  Genprex Demonstrates Growth and Expansion Through Recent Achievements Business Wire +7.29%
Aug-06-19 08:00AM  Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex Clinical Development Program Business Wire -5.85%
Jul-31-19 08:30AM  Genprex Begins Next Phase of Drug Branding Program Business Wire
Jul-09-19 01:58PM  5 Immunotherapy Stocks to Keep a Close Eye On GuruFocus.com
Jul-01-19 08:30AM  Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer Business Wire
May-31-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment GlobeNewswire
May-30-19 08:35AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs GlobeNewswire
May-21-19 08:30AM  Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum Business Wire
May-09-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies GlobeNewswire
May-08-19 08:30AM  Genprex Retains Addison Whitney for Drug Nomenclature Branding Business Wire
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment GlobeNewswire
Apr-12-19 09:00AM  Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer Newsfile
09:00AM  Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable GlobeNewswire
Apr-11-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment GlobeNewswire
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies Newsfile
Apr-08-19 08:30AM  Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting Business Wire
Apr-01-19 08:30AM  Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018 Business Wire +5.79%
Mar-29-19 09:00AM  Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment Newsfile -6.23%
09:00AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy GlobeNewswire
Mar-28-19 08:30AM  Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy Newsfile
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments GlobeNewswire
Mar-19-19 08:30AM  Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire GlobeNewswire
Mar-15-19 09:00AM  NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy Newsfile
08:30AM  NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.s Innovative Approach to Gene Therapy GlobeNewswire
Mar-14-19 08:30AM  NetworkNewsWire Announces Publication on Gene Therapys Promise for Improving Patient Treatments and Market Profitability GlobeNewswire +36.08%
08:30AM  Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City Business Wire
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com +5.33%
Feb-27-19 08:30AM  Genprex Strengthens Senior Team and Continues to Advance Operations Business Wire
Feb-19-19 08:30AM  Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors Business Wire -5.27%
Jan-23-19 08:30AM  Genprex to Present at NobleConXV in Fort Lauderdale, Florida Business Wire
Jan-03-19 08:30AM  Genprex to Present at Biotech Showcase 2019 in San Francisco Business Wire -8.58%
Dec-25-18 01:14PM  Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock? Simply Wall St.
Dec-12-18 08:30AM  Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019 Business Wire
Dec-03-18 08:30AM  Genprex to Present at the 11th Annual LD Micro Main Event Business Wire -8.55%
Nov-20-18 08:30AM  Genprex Provides Clinical and Corporate Update for Third Quarter 2018 Business Wire
Oct-30-18 08:00AM  Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations Business Wire +8.54%
Oct-01-18 08:00AM  Genprex to Present at Upcoming Investor and Industry Conferences Business Wire -5.29%
Sep-27-18 08:00AM  Genprex Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program Business Wire
Aug-21-18 08:30AM  Genprex to Present at Upcoming Investor Conferences Business Wire
Aug-15-18 08:30AM  Genprex Provides Clinical and Corporate Update for Second Quarter 2018 Business Wire
Aug-02-18 08:30AM  Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer Business Wire
Jul-26-18 08:30AM  Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies Business Wire
Jul-18-18 04:17PM  Genprex To Present At The Singular Research Summer Solstice 2018 Conference PR Newswire
Jul-02-18 09:30AM  Diamond Equity Research Initiates Coverage on Genprex Inc. (NASDAQ: GNPX) with a Valuation of $13 Per Share GlobeNewswire
Jun-26-18 08:00AM  Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program PR Newswire +11.46%
May-31-18 08:30AM  Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program PR Newswire +10.30%
May-29-18 08:30AM  Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell PR Newswire
May-23-18 10:55AM  Genprex To Present At Upcoming Investor And Industry Conferences PR Newswire
May-08-18 08:00AM  Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program PR Newswire +15.22%
May-07-18 08:05AM  Genprex To Present At 2018 Disruptive Growth & Healthcare Conference PR Newswire
08:00AM  Genprex Announces $10 Million Private Placement PR Newswire
Apr-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Genprex and Celgene ACCESSWIRE +38.27%
Apr-26-18 08:05AM  Genprex, New IPO in Biotech Generates Investor Interest with Lung Cancer Program ACCESSWIRE +86.76%
Apr-25-18 08:00AM  Genprex Expands Operations to Cambridge, Mass ACCESSWIRE +18.28%
Apr-18-18 09:00AM  Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences PR Newswire
Apr-16-18 09:00AM  Genprex Provides Clinical and Corporate Update PR Newswire -5.46%
Apr-11-18 09:00AM  Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy PR Newswire +7.84%
Apr-10-18 08:35AM  Genprex (GNPX) Stock: May Offer Significant Growth Opportunity ACCESSWIRE -6.53%
Apr-04-18 08:30AM  Genprex Announces Closing of Initial Public Offering PR Newswire -6.34%
Mar-29-18 08:30AM  Genprex Announces Pricing of Initial Public Offering of Common Stock PR Newswire
Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.